Skip to main content
OpenTrials
Completed

NCT Number: NCT00732602

The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes

The purpose of this study is to determine whether Glucose-dependent Insulinotropic Polypeptide (GIP) or Glucagon Like Peptide 2 (GLP-2) has an affect on the secretion of Glucagon from the pancreas in patients with type 1 diabetes mellitus.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital, Gentofte

Hellerup, Capital Region, 2900, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Caucasians over 18 years with type 1 diabetes (WHO criteria)
  • Arginine test without rise in plasma C-peptide
  • Normal blood Hemoglobin
  • Informed consent

Exclusion criteria

  • Liver disease
  • Diabetic nephropathy
  • Treatment with medications unpausable for 12 hours

Treatment and study plan

GIP-infusion

Other

Sodium-chloride

Other

GLP-2 infusion

Other

Primary outcomes

  1. plasma-glucagon Area Under Curve at 0-90 min. and 90-180 min.

Sponsors and collaborators

Lead sponsor

University Hospital, Gentofte, Copenhagen

Other

Collaborators

  • University of Copenhagen

Registry information

Important dates

Study start
2008
Primary completion
2008
First posted
Aug 12, 2008
Registry last updated
Feb 13, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.